Stroke/systemic embolism rates during the at-risk period were similar in rivaroxaban-treated and warfarin-treated participants ( 0.30 % versus 0.41 % per 30 days ; hazard ratio [ confidence interval ] = 0.74 [ 0.36-1 .50 ] ; P = 0.40 ) .